Potentiation of bradykinin actions by ACE inhibitors

Trends in Endocrinology and Metabolism

Volumn 10, Issue 6, 1999, Pages 223-229

  Erdös, Ervin G ^a   Deddish, Peter A ^a   Marcic, Branislav M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ICATIBANT; KALLIKREIN; KININ; RAMIPRILAT; ANTIBODY; ARGININE CARBOXYPEPTIDASE; KALLIDIN;

ANIMAL CELL; CARDIOVASCULAR EFFECT; CHO CELL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; GENETIC TRANSFECTION; LIGAND BINDING; PEPTIDE SYNTHESIS; RECEPTOR AFFINITY; RECEPTOR BINDING; TACHYPHYLAXIS;

EID: 0033174777     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(99)00156-3     Document Type: Review

References (62)

1. Hunyady L., Balla T., Catt K.J. The ligand binding site of the angiotensin AT1 receptor. Trends Pharmacol. Sci. 17:1996;135-140.
2. Linz W., Wiemer G., Gohlke P., Unger T., Schölkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47:1995;25-49.
3. Odya C.E., Levin Y., Erdös E.G., Robinson C.J.G. Soluble dextran complexes of kallikrein, bradykinin, and enzyme inhibitors. Biochem. Pharmacol. 27:1978;173-179.
4. Auch-Schwelk W., Bossaller C., Claus M., Walther B., Gräfe M., Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc. Res. 27:1993;312-317.
5. Hecker M., Pörsti K., Bara A.T., Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br. J. Pharmacol. 111:1994;238-244.
6. Minshall R.D.et al. Potentiation of the actions of bradykinin by angiotensin I converting enzyme (ACE) inhibitors. The role of expressed human bradykinin B2 receptors and ACE in CHO cells. Circ. Res. 81:1997;848-856.
7. Page, I.H. (1988) The discovery of renin and the relation to hypertension. Hypertension Research. A Memoir 1920-1960, pp 106-123, Pergamon Press.
8. Fritz, H., Schmidt, I. and Dietze, G. (1989) The kallikrein-kinin system in health and disease. International Symposium in Munich, September 12-17, 1988. Limbach-Verlag, p. 374.
9. Rocha e Silva M. The physiological significance of bradykinin. Ann. New York Acad. Sci. 104:1963;190-211.
10. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44:1992;1-80.
11. Colman R.W. Plasma prekallikrein and kallikrein. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. 1998;147-153 Academic Press.
12. Margolius H.S. Kallikreins and kinins - some unanswered questions about system characteristics and roles in human disease. Hypertension. 26:1995;221-229.
13. Clements J.A. The molecular biology of the kallikreins and their roles in inflammation. Farmer S.G. The Kinin System. 1997;71-97 Academic Press.
14. Chao J. Human tissue kallikrein. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. 1998;97-100 Academic Press.
15. Takada Y., Skidgel R.A., Erdös E.G. Purification of human prokallikrein. Identification of the site of activation by the metalloproteinase thermolysin. Biochem. J. 232:1985;851-858.
16. Erdös E.G., Skidgel R.A. Metabolism of bradykinin by peptidases in health and disease. Farmer S.G. The Kinin System. Handbook of Immunopharmacology. 1997;112-141 Academic Press.
17. Erdös, E.G. (1979) Kininases. In Bradykinin, Kallidin and Kallikrein (Supplement to Vol. XXV) (Erdös, E.G., ed.), pp 427-448, Handbook of Experimental Pharmacology, Springer-Verlag.
18. Skidgel R.A., Erdös E.G. Enzymatic breakdown of bradykinin. Said S.I. Pro-inflammatory and Anti-inflammatory Peptides. 1998;459-476 Marcel Dekker.
19. Regoli D., Allogho S.N., Rizzi A., Gobeil F.J. Bradykinin receptors and their antagonists. Eur. J. Pharmacol. 348:1998;1-10.
20. Hess J.F. Molecular pharmacology of kinin receptors. Farmer S.G. The Kinin System. 1997;45-55 Academic Press.
21. Marceau F., Hess J.F., Bachvarov D.R. The B1 receptors for kinins. Pharmacol. Rev. 50:1998;357-386.
22. Pizard A., Marchetti J., Allegrini J., Alhenc-Gelas F., Rajerison R.M. Negative cooperativity in the human bradykinin B2 receptor. J. Biol. Chem. 273:1998;1309-1315.
23. Yang H.Y.T., Erdös E.G. Second kininase in human blood plasma. Nature. 215:1967;1402-1403.
24. Yang H.Y.T., Erdös E.G., Levin Y. Characterization of a dipeptide hydrolase (kininase II; angiotensin I converting enzyme). J. Pharmacol. Exp. Ther. 177:1971;291-300.
25. Wei L., Alhenc-Gelas F., Corvol P., Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266:1991;9002-9008.
26. Williams T.A., Corvol P., Soubrier F. Identification of two active site residues in human angiotensin-I converting enzyme. J. Biol. Chem. 269:1994;29430-29434.
27. Corvol P., Williams T.A. Peptidyl-dipeptidase A/angiotensin I-converting enzyme. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. 1998;1066-1076 Academic Press.
28. Skidgel, R.A. and Erdös, E.G. (1993) Biochemistry of angiotensin converting enzyme. In The Renin-Angiotensin System (Vol. 1) (Robertson, J.I.S. and Nicholls, M.G., eds), pp 10.1-10.10, Gower Medical Publishers.
29. Kumar K.S., Kusari J., Roy S.N., Soffer R.L., Sen G.C. Structure of testicular angiotensin-converting enzyme: a segmental mosaic enzyme. J. Biol. Chem. 264:1989;16754-16758.
30. Soubrier F., Hubert C., Testus P., Nadaud S., Alhenc-Gelas F., Corvol P. Molecular biology of the angiotensin I converting enzyme: I. Biochemistry and structure of the gene. J. Hypertens. 11:1993;471-476.
31. Soubrier F., Wei L., Hubert C., Clauser E., Alhenc-Gelas F., Corvol P. Molecular biology of the angiotensin I converting enzyme: II. Structure-function. Gene polymorphism and clinical implications. J. Hypertens. 11:1993;599-604.
32. Gavras H.G., Faxon D.P., Berkoben H.R., Ryan T.J. Angiotensin converting enzyme inhibition in patients with heart failure. Circulation. 58:1978;770-776.
33. Gavras H. Angiotensin converting enzyme inhibition and the heart. Hypertension. 23:1994;813-818.
34. Gavras H., Gavras I. Bioactive peptides in the treatment of hypertension and heart failure. Mavromoustakos J. Bioactive Peptides in Drug Discovery and Design: Medical Aspects. 11-50 IOS Press. (in press).
35. Pfeffer J.M., Fischer T.A., Pfeffer M.A. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu. Rev. Physiol. 57:1995;805-826.
36. Pfeffer M.A., Braunwald I., Moye L.A. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. New Engl. J. Med. 327:1992;669-677.
37. Lewis E.J. Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. Koide H., Ichikawa I. Progression of Chronic Renal Diseases. Contrib. Nephrol. 118:1996;206-213 Karger.
38. Carretero, O.A. & Scicli, A.G. (1995) The kallikrein-kinin system as a regulator of cardiovascular and renal function. In Hypertension: Pathophysiology, Diagnosis, and Management (2nd Edn) (Laragh, J.H. & Brenner, B.M., eds), pp 983-999, Raven Press Publishers.
39. Schölkens B.A., Linz W., König W. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischemic rat heart are abolished by a bradykinin antagonist. J. Hypertens. 6(Suppl. 4):1988;S25-S28.
40. Linz W., Jessen T., Becker R.H.A., Schölkens B.A., Wiemer G. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation. 96:1997;3164-3172.
41. Morris S.D., Yellon D.M. Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J. Am. Coll. Cardiol. 29:1997;1599-1606.
42. Parratt J.R., Vegh A., Papp J.G. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning: a brief review of the evidence. Can. J. Physiol. Pharmacol. 73:1995;837-842.
43. Gainer J.V., Morrow J.D., Loveland A., King D.J., Brown N.J. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. New Engl. J. Med. 339:1998;1285-1292.
44. Vogel R., Werle E., Zickgraf-Rüdel G. Neure Aspekte der Kininforschung. I. Potenzierung und Blockierung der biologischen Kininwirkung. Z. Klin. Chem. Klin. Biochem. 8:1970;177-185.
45. Stewart M.J., Ferreira S.H., Greene L.J. Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro - an inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II. Biochem. Pharmacol. 20:1971;1557-1567.
46. Ondetti M.A. From peptides to peptidases: a chronicle of drug discovery. Annu. Rev. Pharmacol. 34:1994;1-16.
47. Hecker M., Blaukat A., Bara A.T., Müller-Esterl W., Busse R. ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br. J. Pharmacol. 121:1997;1475-1481.
48. Ufkes J.G.R., Aarsen P.N., van der Meer C. The mechanism of action of two bradykinin-potentiating peptides on isolated smooth muscle. Eur. J. Pharmacol. 44:1977;89-97.
49. Rabito S.F., Minshall R.D., Swaminathan B., Tan M.N., Igíc R., Erdös E.G. Mode of potentiation of the effects of bradykinin by angiotensin I converting enzyme inhibitors on the guinea pig ileum. Anesthesiology. 89(3A):1998;A635. (abstr.).
50. Minshall R.D., Erdös E.G., Vogel S.M. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am. J. Cardiol. 80:1997;A132-A136.
51. 2 receptor. Hypertension. 33:1999;835-843.
52. Blaukat A., Abd Alla S., Lohse M.J., Müller-Esterl W. Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J. Biol. Chem. 271:1996;32366-32374.
53. 1 MF-2 smooth muscle cells. J. Biol. Chem. 272:1997;17858-17866.
54. 1, MF-2 smooth muscle cells. J. Biol. Chem. 262:1987;3098-3105.
55. Roberts R.A., Gullick W.J. Bradykinin receptors undergo ligand-induced desensitization. Biochemistry. 29:1990;1975-1979.
56. Deddish P.A., Marcic B., Jackman H.L., Wang H-Z., Skidgel R.A., Erdös E.G. N-domain specific substrates and C-domain inhibitors of angiotensin converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 31:1998;912-917.
57. Brosnihan K.B., Li P., Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 27:1996;523-528.
58. Deddish P.A.et al. Naturally occurring active N-domain of human angiotensin I converting enzyme. Proc. Natl. Acad. Sci. U. S. A. 91:1994;7807-7811.
59. Yu H., Carretero O.A., Juncos L.A., Garvin J.L. Biphasic effect of bradykinin on rabbit afferent arterioles. Hypertension. 32:1998;287-292.
60. Liu Y-H., Yang X-P., Sharov V.G., Sigmon D.H., Sabbah H.N., Carretero O.A. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 27:1996;7-13.
61. 1 MF-2 smooth muscle cells is paralleled by sequestration of the occupied receptors. Arch. Biochem. Biophys. 301:1993;336-344.
62. Benzing T., Fleming I., Blaukat A., Müller-Esterl W., Busse R. The ACE inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation. 99:1999;2034-2040.